Pfizer (PFE) AI Stock Analysis

• Market Cap: $137.93B
• Dividend Yield: 7.09%
• Average Volume (3M): 38.16M
• Price to Earnings (P/E): 17.6
• Beta (1Y): 0.27
• Revenue Growth: 13.38%
• EPS Growth: N/A
• Country: US
• Employees: 81,000
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.92
• Shares Outstanding: 5,685,365,700
• 10 Day Avg. Volume: 39,496,704
• 30 Day Avg. Volume: 38,155,411
• PEG Ratio: -8.13
• Price to Book (P/B): 1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.15
• Enterprise Value/Market Cap: 1.42
• Enterprise Value/Revenue: 0.81
• Enterprise Value/Gross Profit: 4.66
• Enterprise Value/Ebitda: 3.59
• 1Y Price Target: $28.38
• Price Target Upside: 17.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 18

• Rating: 72 Outperform
• Price Target: $27.00 ▲(11.62%Upside)

Pfizer's overall score is primarily driven by its solid financial performance and attractive valuation, enhanced by positive technical indicators. Despite some revenue decline and external challenges highlighted in the earnings call, the company's strategic focus and operational efficiency support a stable outlook.

Positive Factors

Business Strategy

A number of transformative acquisitions completed using the windfall of COVID cash bolster the company's pipeline.

Financial Performance

The analyst's Outperform rating on Pfizer shares is supported by the analysis suggesting that the shares are undervalued given potentially better fundamentals relative to U.S. BioPharma peers.

Product Development

Pfizer's KAT6 inhibitor has demonstrated strong responses at ASCO with objective response rate of around 37% and median progression-free survival of 10.7 months in ER+/HER2- metastatic breast cancer.

Negative Factors

Market Competition

Efficacy with the go-forward dose of PDL1V monotherapy appears undifferentiated compared to other ADCs in the relapsed/refractory metastatic NSCLC space.

Product Safety

Patients receiving the Braftovi combination therapy experienced more adverse events compared to those on standard-of-care.

Pfizer Business Overview & Revenue Model

Company Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

How the Company Makes Money

Pfizer makes money primarily through the sale of pharmaceutical products, which is its largest revenue stream. The company's revenue model is based on the development and commercialization of patented drugs, which are sold to hospitals, pharmacies, and directly to healthcare providers. Key revenue streams include its blockbuster drugs and vaccines, such as those in oncology, vaccines (including the COVID-19 vaccine), and rare diseases. Pfizer also generates revenue through strategic partnerships and collaborations with other pharmaceutical companies and research institutions, which help in the development and distribution of new therapies. Additionally, Pfizer invests heavily in research and development to sustain its pipeline of future products, ensuring a continuous flow of new revenue-generating medicines.

Pfizer Financial Statement Overview

Summary

Pfizer demonstrates solid financial health with strong margins and cash flow generation capabilities. Despite a recent dip in revenue growth and ROE, the company maintains a stable balance sheet with a manageable debt level. Continued focus on operational efficiencies and strategic investments will be key to sustaining growth and improving profitability.

Income Statement

Pfizer's income statement reflects a strong gross profit margin of 67.38% for TTM, indicating efficient cost management. However, there is a decline in revenue growth with a decrease of 1.83% from the previous annual report. The net profit margin stands at 12.60% for TTM, showing profitability but lower than the peak in 2022. EBIT and EBITDA margins are healthy at 23.65% and 27.59% respectively, yet have decreased from prior years, signaling potential challenges in maintaining operational efficiency.

Balance Sheet

The balance sheet indicates a stable financial structure with a debt-to-equity ratio of 0.68, which is manageable. The equity ratio is at 43.42%, showcasing a solid equity base relative to total assets. Return on equity for TTM is 8.71%, reflecting decent profitability on shareholder investment, though it has declined from previous years, suggesting room for improvement in generating returns.

Cash Flow

Cash flow analysis shows strong free cash flow generation, with a growth rate of 14.11% from the previous year, highlighting robust cash generation capabilities. The operating cash flow to net income ratio is 1.78, indicating good conversion of income to cash. However, the free cash flow to net income ratio is 1.43, suggesting some limitations in free cash flow relative to net income, which may affect future investment or debt repayment flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.46B	63.63B	58.50B	100.33B	81.29B	41.91B
Gross Profit	42.09B	47.21B	28.81B	65.99B	50.47B	33.22B
EBITDA	17.23B	18.13B	9.56B	41.03B	30.79B	13.17B
Net Income	7.87B	8.03B	2.12B	31.37B	21.98B	7.02B
Balance Sheet
Total Assets	208.03B	213.40B	226.50B	197.21B	181.48B	154.23B
Cash, Cash Equivalents and Short-Term Investments	17.32B	20.48B	12.69B	22.73B	31.07B	12.22B
Total Debt	61.29B	63.65B	70.84B	34.87B	37.00B	38.27B
Total Liabilities	117.39B	124.90B	137.21B	101.29B	104.01B	90.76B
Stockholders Equity	90.34B	88.20B	89.01B	95.66B	77.20B	63.24B
Cash Flow
Free Cash Flow	11.22B	9.84B	4.79B	26.03B	29.87B	11.61B
Operating Cash Flow	13.99B	12.74B	8.70B	29.27B	32.58B	14.40B
Investing Cash Flow	4.19B	2.65B	-32.28B	-15.78B	-22.55B	-4.27B
Financing Cash Flow	-17.44B	-17.14B	26.07B	-14.83B	-9.82B	-9.65B

Pfizer Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Positive. The current price of 24.19 is above the 20-day moving average (MA) of 23.98, above the 50-day MA of 23.26, and below the 200-day MA of 25.14, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 56.12 is Neutral, neither overbought nor oversold. The STOCH value of 44.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PFE.

Pfizer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	78 Outperform	$200.05B	11.60	39.31%	4.11%	4.40%	654.93%
JNJ	75 Outperform	$365.75B	16.93	29.45%	3.42%	-0.37%	29.21%
AZN	73 Outperform	$218.28B	27.79	19.81%	3.00%	15.48%	22.70%
ABBV	73 Outperform	$327.47B	79.05	88.15%	3.51%	5.45%	-30.21%
PFE	72 Outperform	$137.93B	17.58	8.62%	7.09%	13.38%	―
AMGN	71 Outperform	$150.75B	25.59	105.67%	3.40%	15.59%	56.99%
Sector *	60 Neutral	HK$15.14B	5.55	-7.43%	5.48%	11.72%	-20.69%

Pfizer Corporate Events

Pfizer Completes €3.3 Billion Notes Offering

On May 19, 2025, Pfizer Netherlands International Finance B.V., a subsidiary of Pfizer Inc., completed a public offering of €3.3 billion in aggregate principal amount of notes with varying maturity dates and interest rates. This strategic financial move, backed by a senior unsecured guarantee from Pfizer Inc., is part of the company’s broader financial strategy to strengthen its market position and ensure operational liquidity.

The most recent analyst rating on (PFE) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.